| James A Wright, MD | |
|
420 E Division St, Fond Du Lac, WI 54935-4560 | |
| (920) 926-8495 | |
| Not Available |
| Full Name | James A Wright |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 38 Years |
| Location | 420 E Division St, Fond Du Lac, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740273390 | NPI | - | NPPES |
| 32272800 | Medicaid | WI | |
| 340013156 | Other | WI | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 28621 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Agnes Hospital | Fond du lac, WI | Hospital |
| Ripon Medical Center | Ripon, WI | Hospital |
| Waupun Memorial Hospital | Waupun, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Agnesian Healthcare Inc | 1658289624 | 319 |
News Archive
WHO reported there were 4 additional suspected cases. Three out of the four suspects were relatives of the 20-year-old nurse and the fourth suspect is a male patient who stayed in the same ward.
ORFLO Technologies announced the international launch of Moxi Z, the life science industry's first hands-free mini automated cell counter at the American Association for Cancer Research Annual Meeting in Orlando.
BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended June 30, 2009.
› Verified 5 days ago
| Entity Name | Agnesian Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346228541 PECOS PAC ID: 1658289624 Enrollment ID: O20031104000263 |
News Archive
WHO reported there were 4 additional suspected cases. Three out of the four suspects were relatives of the 20-year-old nurse and the fourth suspect is a male patient who stayed in the same ward.
ORFLO Technologies announced the international launch of Moxi Z, the life science industry's first hands-free mini automated cell counter at the American Association for Cancer Research Annual Meeting in Orlando.
BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended June 30, 2009.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James A Wright, MD 420 E Division St, Fond Du Lac, WI 54935-4560 Ph: (920) 926-8343 | James A Wright, MD 420 E Division St, Fond Du Lac, WI 54935-4560 Ph: (920) 926-8495 |
News Archive
WHO reported there were 4 additional suspected cases. Three out of the four suspects were relatives of the 20-year-old nurse and the fourth suspect is a male patient who stayed in the same ward.
ORFLO Technologies announced the international launch of Moxi Z, the life science industry's first hands-free mini automated cell counter at the American Association for Cancer Research Annual Meeting in Orlando.
BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended June 30, 2009.
› Verified 5 days ago
Christopher C Tuveson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 420 E Division St, Fond Du Lac, WI 54935 Phone: 920-926-8495 | |
Sean P Hedican, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 420 E Division St, Fond Du Lac, WI 54935 Phone: 209-268-4959 Fax: 920-926-8386 | |
James E Cauley, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 420 E Division St, Fond Du Lac, WI 54935 Phone: 920-926-8495 Fax: 920-926-8386 | |
Aaron R Johnson, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 420 E Division St, Fond Du Lac, WI 54935 Phone: 920-926-8495 |